Get started
Author

Admasu Tenna Mamuye

Observed names: Admasu Mamuye, Admasu T. Mamuye
ORCID: 0000-0002-9882-9989
Observed ORCID: 0000-0002-9882-9989
OpenAlex ID: A5077703229
Factors associated with mortality of TB/HIV co-infected patients in Ethiopia
2017 · Alula M. Teklu, Abiy Nega, et al. · Ethiopian Journal of Health Sciences · 51
PDF
Point-of-Care Testing for Cryptococcal Disease Among Hospitalized Human Immunodeficiency Virus–Infected Adults in Ethiopia
2016 · Admasu Tenna Mamuye, Ethan Bornstein, et al. · American Journal of Tropical Medicine and Hygiene · 24
Breakthrough tuberculosis disease among people with HIV – Should we be worried? A retrospective longitudinal study
2019 · Kesetebirhan Delele Yirdaw, Alula M. Teklu, et al. · PLoS ONE · 16
PDF
Targeted Delivery of BZLF1 to DEC205 Drives EBV-Protective Immunity in a Spontaneous Model of EBV-Driven Lymphoproliferative Disease
2021 · Elshafa Hassan Ahmed, Eric Brooks, et al. · Vaccines · 11
PDF
A Phase 1, Open-Label, Dose-Escalation and Expansion, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MT-0169 in Patients with Relapsed or Refractory Multiple Myeloma or Non-Hodgkin Lymphoma
2022 · Bhagirathbhai Dholaria, Admasu Mamuye, et al. · Blood · 5
447 Interim results of a phase 1 study of the novel engineered toxin body TAK-169 in patients with relapsed or refractory multiple myeloma
2021 · Shaji Kumar, Admasu Mamuye, et al. · Journal for ImmunoTherapy of Cancer · 5
PDF
Abstract CT191: First-in-human, dose escalation and expansion study of MT-6402, a novel engineered toxin body (ETB) targeting PD-L1, in patients with PD-L1 expressing relapsed/refractory advanced solid tumors: Interim data
2024 · Brian A. Van Tine, Eugene Ahn, et al. · Cancer Research
Abstract OT2-11-01: A phase 1 study of the novel immunotoxin MT-5111 in patients with HER2+ tumors: interim results
2023 · Meena Okera, Brian A. Van Tine, et al. · Cancer Research
Works count: 8
Citation count: 112
H-index: 5
I10-index: 4
Year
Topic
Type